Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

James Poole

Pediatrics Wake Forest, NC Medical Doctor

NPI 1124087978 CMS profile 278196

11130 Capital Blvd, Wake Forest, NC 27587

Open in the dashboard

General payments

$6,804

114 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, James Poole of Wake Forest, NC is reported in the CMS Open Payments database as having received $6,804 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $22 1
2021 General $387 21
2020 General $511 48
2019 General $5,883 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Poole
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to James Poole were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year James Poole Pediatrics median Middle half National median
2019 $5,883 $86 $31–$183 $163
2020 $511 $49 $22–$110 $114
2021 $387 $68 $27–$158 $132
2022 $22 $77 $30–$173 $149
2023 $0 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Ironshore Pharmaceuticals Inc. $5,172 26 payments
  2. Neos Therapeutics, LP $941 32 payments
  3. Tris Pharma Inc $402 45 payments
  4. Supernus Pharmaceuticals, Inc. $125 1 payment
  5. Adlon Therapeutics L.P. $87 6 payments
  6. Neurocrine Biosciences, Inc. $22 1 payment
  7. Boston Scientific Corporation $22 1 payment
  8. Takeda Pharmaceuticals U.S.A., Inc. $17 1 payment
  9. Arbor Pharmaceuticals, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Consulting Fee $4,550 2 payments
  2. Food and Beverage $1,792 110 payments
  3. Travel and Lodging $462 2 payments
Products named General payments · program years 2019–2022
  1. Jornay PM 20mg capsules (Bottle of 100) $4,947 16 payments
  2. Adzenys XR-ODT $927 31 payments
  3. COTEMPLA XR-ODT $927 31 payments
  4. Dyanavel XR $228 25 payments
  5. JORNAY PM $226 10 payments
  6. QELBREE $125 1 payment
  7. Quillivant XR $92 10 payments
  8. ADHANSIA XR $87 6 payments
  9. Quillivant $74 8 payments
  10. INGREZZA $22 1 payment
  11. Other $76 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Pediatric Medicine: 38

Drug cost

$868

Median for Pediatric Medicine: $2,769

Branded share of claims

100%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 14 $868

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record